Irene Wobusobozi
ID:
|
UTILIZATION OF LABORATORY TESTS TO GUIDE ANTIBIOTIC PRESCRIPTION: A CASE STUDY OF MUKONO GENERAL HOSPITAL
REFNo: HS4785ES
1. To determine the proportion of patients for whom biomarker tests were done. 2. To determine the proportion of patients with antibiotic prescriptions based on biomarker test results 3. To assess the turnaround time for the processing and referring microbial samples 4. To explore the barriers and facilitators of using laboratory tests to guide antibiotic prescription in Mukono Hospital. ,
|
Uganda |
2024-10-08 17:36:15 |
2027-10-08 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
WINNIE ACHOLA STELLA
ID: UNCST-2026-R024263
|
IMPACT OF STONE QUARRYING ACTIVITIES ON AIR, WATER QUALITY AND ASSOCIATED SELF-REPORTED RESPIRATORY SYMPTOMS: A CASE STUDY OF TE-DAM STONE QUARRY SITE IN GULU CITY
REFNo: NS1272ES
1. To determine the concentrations of particulate matter (PM10 and PM2.5) at varying distances from selected stone quarry sites in Te-dam.
2. To determine the physicochemical parameters (pH, turbidity, total dissolved solids, total suspended solids, nitrates, nitrites, iron, and color) of the surface water near Te-Dam quarry site.
3. To assess the perceived respiratory and water related health effects associated with air and water quality deterioration resulting from stone quarrying activities on individuals around Te Dam.
|
Uganda |
2026-06-25 22:04:22 |
2029-06-25 |
Natural Sciences |
Non-Clinical Trial |
Degree Award |
|
WINNIE NAMBATYA
ID:
|
Risk factors for Neural Tube Defects among children attending Mulago and Kawempe Hospitals: A case control study
REFNo: HS430ES
1. To determine the types of NTDs in Mulago National Referral Hosptial among infants,
2. To determine the factors associate with the NTDs,
3. To compare the factors with the type of NTD
|
Uganda |
2019-08-20 |
2022-08-20 |
Medical and Health Sciences |
|
Non-degree Award |
|
WINNIE NAMBATYA
ID:
|
Evaluation of the complexity of medicine regimens and drug therapy problems among children with sickle cell anemia in Jinja Regional Referral Hospital: A prescription audit
REFNo: HS1299ES
• To determine the complexity of medication regimens prescribed to the patients with SCA.
• To determine the incidence of DTPs among medications prescribed to children with SCA.
|
Uganda |
2021-05-20 |
2024-05-20 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Winnifred Namazzi Birabwa
ID: UNCST-2025-R017998
|
AN ASSESSMENT FOR THE APPROPRIATE CULTURALLY RESPONSIVE PEDAGOGY IN IMPLEMENTING THE COMPETENCY BASED CURRICULUM AMONG INDIGENOUS BATWA COMMUNITIES IN UGANDA
REFNo: SS4097ES
1. What Batwa culturally responsive learning experiences can teachers integrate in teaching to effectively implement the CBC in Batwa heterogeneous classrooms?
2. How can the teachers utilize Batwa learners’ cultural backgrounds to address their learning needs when implementing the CBC in Batwa heterogeneous classrooms?
3. How can teachers integrate culturally responsive teaching methods to enable effective implementation of the CBC in Batwa heterogeneous classrooms?
4. What are the challenges of integrating CRP into the implementation of the competency based curriculum in Batwa heterogeneous classrooms?
|
Uganda |
2025-09-12 16:53:22 |
2028-09-12 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Winfred Naamara
ID:
|
Understanding social support for family caregivers of patients with schizophrenia in greater Kampala metropolitan area, Uganda
REFNo: SS1038ES
The overall objective of this study is to examine how family caregivers of patients with schizophrenia generate and experience social support in greater Kampala metropolitan area.
|
Uganda |
2021-10-19 |
2024-10-19 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
Tuberculosis, Alcohol, and Lung Comorbidities (TALC) Study
REFNo: HS2705ES
Qualitatively evaluate factors for tailoring pharmaco-behavioral alcohol and smoking interventions in PLWH being treated for TB. ,Explore how smoking alters the association of past-month heavy drinking and post-TB lung disease progression over time,• Aim 1b. Assess the association of past-month heavy drinking and post-TB lung disease progression over time. This aim uses recent alcohol use (30-day Timeline Followback, PEth) since direct mechanisms (e.g., alcohol toxicity) may drive the physiologic, anatomic, and immunologic outcomes of interest. We define past-month heavy drinking as ?7 drinks/week (women), ?14 drinks/week (men) or PEth>200 ng/mL.,• Aim 1a. Determine if past-year hazardous drinking is associated with post-TB lung disease. ,Aim 1. Determine the relationship between hazardous drinking and post-TB lung disease in PLWH.,
|
Uganda |
2023-03-24 2:08:05 |
2026-03-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
TB Risk by Alcohol Consumption
REFNo: HS1962ES
To determine the incidence of active TB disease among PLWH with prior LTBI, who received TPT, by level of alcohol use.
To estimate the incidence rate of new TB infection among PLWH with prior negative TST results by level of alcohol use.
To examine the risk of acquiring TB infection and of incident active TB disease among PLWH with heavy alcohol use after receipt of TPT in PLWH in Uganda.
|
Uganda |
2021-12-15 |
2024-12-15 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
The Sentinel Research Network of IeDEA: A Prospective Cohort among People Living with HIV
REFNo: HS2217ES
Determine cross-sectional prevalence, incidence and progression over three years of liver enzyme (ALT/AST) elevation, non-invasive biomarkers of liver fibrosis (APRI, FiB-4, Fibroscan) and liver steatosis (CAP, Fatty Liver Index,Characterize the onset, chronicity and severity of mental health and substance use problems among older PLHIV over time as well as their interrelation and their influence on the HIV care continuum.,Determine the prevalence, incidence and predictors of cardio-metabolic disorders including diabetes mellitus, hypertension and dyslipidemia in PLHIV during a three-year follow-up period,To establish the IeDEA Sentinel Research Network (IeDEA-SRN)to prospectively capture and analyze standardized data among PLHIV in LMICs. Through this network, we further seek to implement studies focused on cardiovascular risk factors, mental health and substance use, as well as liver disease among PLHIV accessing HIV care in LMICs,
|
Uganda |
2022-09-06 15:07:47 |
2025-09-06 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
HIV-1 subtype-specific drug resistance in patients failing dolutegravir-based first-line, second-line or third-line regimens: multiregional study (DTG resist study)”
REFNo: HS2435ES
Main Objective
1.To determine the patterns and spectrum of InSTI DRMs in adults and adolescents with virologic failure on DTG-based ART by ART regimen and HIV-1 subtype.
2. To identify risk factors for virologic failure, InSTI DRMs, and InSTI drug resistance in adolescents and adults on DTG-based ART, including drug, host and health system factors.
Specific Objectives
1a) To identify the prevalence of InSTI DRMs at the time of virologic failure.
1b) To compare the prevalence of InSTI DRMs at the time of virologic failure between HIV-1 subtypes and treatment contexts.
2a) To identify risk factors for Virologic Failure
2b) To identify risk factors for Drug Resistance Mutations.
3. To investigate correlations between novel resistance genotypes and phenotypic DTG resistance across HIV-1 subtypes.
|
Uganda |
2022-10-05 15:04:09 |
2025-10-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
IeDEA East Africa Tuberculosis Sentinel Research Network (IeDEA-EA TB-SRN)
REFNo: HS2619ES
3. To describe post-TB lung disease (PTLD) and associations with HIV infection, diabetes, chronic lung disease, and tobacco and alcohol use, including measuring physiologic, structural, and functional impairment, health-related quality of life, and survival,2. To assess the individual-level effects of HIV and antiretroviral therapy (ART) on TB symptomatology, diagnosis, treatment response, and survival. ,1. To collect and analyze clinical and treatment data among people treated for pulmonary TB with or without HIV-co-infection, in order to improve understanding of the prognosis of TB disease and its health-related outcomes, including quality of life and survival.,The overarching objective/aim of the study is to assess pulmonary TB treatment and longer-term outcomes among people with and without HIV in TB-SRN sites in order to inform policy and practice around TB treatment and create a platform for additional TB research within IeDEA. ,
|
Uganda |
2023-01-11 12:47:27 |
2026-01-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa.(RESOLVE)
REFNo: HS2620ES
Aim 2: Use simulation modeling to examine the clinical impact, costs, and cost-effectiveness of strategies to improve viral suppression after virologic failure on TLD. We will populate the previously validated Cost-Effectiveness of Preventing AIDS Complications-International (CEPAC-I) model with the novel clinical trial data from Aim 1 to project long-term clinical outcomes and cumulative lifetime costs. We will then compare the cost-effectiveness of the three strategies evaluated in Aim 1 for addressing virologic failure among people treated with first-line TLD in Uganda or South Africa. ,Aim 1: Conduct a randomized clinical trial to determine the optimal strategy for management of virologic failure on first-line TLD in SSA. We will recruit 648 adolescents and adults with two viral loads >1,000 copies/mL while on first-line TLD for at least 12 months, who are in care at one of six public-sector HIV clinics in Uganda or South Africa. We will randomize participants to one of the following strategies, stratified by clinic and prior NNRTI-exposure: a) Maintenance on TLD with switch to protease inhibitor (PI)-based second-line ART if virologic failure persists past six months; b) Individualized Care, with regimen choice based on results of genotypic resistance tests and urine tenofovir assays; or c) Immediate Switch to PI-based second-line ART. The primary outcome will be viral suppression (<50 copies/mL) at 48 weeks post-enrollment using the FDA snapshot definition. We hypothesize that rates of viral suppression at 48 weeks will be higher in the Individualized Care arm than in the Maintenance on TLD and Immediate Switch arms.,
|
Uganda |
2023-02-09 11:06:56 |
2026-02-09 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
Gabapentin to Reduce Alcohol and Improve Viral Load Suppression (GRAIL) – “Promoting Treatment as Prevention”
REFNo: HS2622ES
2. To assess the impact of gabapentin compared to placebo on: a) alcohol consumption; b) pain severity; c) ART adherence; and d) engagement in HIV care, in order to explore potential mechanisms by which gabapentin may lead to HVL suppression.,1. To test the efficacy of gabapentin versus placebo to achieve undetectable HVL (Primary Outcome at 3 months; Secondary Outcome at 6 & 12 months),
|
Uganda |
2023-01-18 18:33:54 |
2026-01-18 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
The Phosphatidylethanol (PEth) Results Communication (PERC) Study
REFNo: HS4449ES
Main Objective: To develop and pilot strategies for using PEth results communication to boost alcohol brief interventions for PWH and explore their acceptability, appropriateness, and feasibility for a future large-scale Randomized Controlled Trial.
AIM 1: Develop approaches for adding PEth results communication to alcohol brief interventions.
AIM 2. Explore the acceptability, appropriateness, and feasibility of adding PEth results communication to an alcohol brief intervention in a pilot randomized controlled trial (RCT).
|
Uganda |
2024-09-12 11:23:21 |
2027-09-12 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
Exploring low-level HIV viremia among individuals on dolutegravir in sub-Saharan Africa (Low-V Africa Study).
REFNo: HS7580ES
Aim 2: To elucidate pharmacologic, viral, and host factor determinants of the progression to VF among participants in the Low-V Africa Cohort. In doing so, we will also characterize the prevalence of these factors in the setting of pLLV in the Low-V Africa cohort. We will evaluate viral suppression and long-term persistence of LLV as secondary outcomes. Analyses will employ longitudinal modeling with repeated measures, as well as machine learning techniques. Aim 2a will assess adherence, as measured by TFV-DP levels from DBS, as a predictor of VF after pLLV. Aim 2b will assess HIV drug resistance, defined by GSS, as a predictor of VF after pLLV. Aim 2c will evaluate the impact of a hyperactive HIV-1 viral reservoir, identified with long-range plasma SGS and MIP-Seq, on the risk of VF after pLLV. Aim 2d will estimate the relative contributions of adherence, resistance, and the reservoir to VF after pLLV. ,Aim 1: To determine longitudinal outcomes of individuals with pLLV while on tenofovir/lamivudine/dolutegravir (TLD). We will enroll a cohort of 200 adults in Uganda with pLLV (Low-V Africa Cohort), defined as at least two consecutive VLs ranging 50-1,000 copies/mL while on TLD for at least 12 months. We will follow participants for 96 weeks and will collect plasma, dried blood spots (DBS), and peripheral blood mononuclear cells (PBMCs) at enrollment, as well as 24-, 48-, and 96-week study visits. Aim 1a will estimate the 96-week cumulative incidence of VF and poor clinical outcomes after pLLV. We will perform VL quantification at each study visit to determine whether participants progress to virologic failure (>1,000 copies/mL), achieve viral suppression (<50 copies/mL), or have persistence of LLV. As secondary outcomes, we will also estimate the cumulative incidence of opportunistic infections, hospitalization, and death. Aim 1b will determine the 96-week cumulative incidence of emergent HIV drug resistance and a hyperactive reservoir in PWH with pLLV. We will perform Sager sequencing of plasma specimens with VLs >500 copies/mL and long-range plasma single-genome HIV RNA sequencing (SGS) of plasma specimens with VLs ?500 copies/mL at each time point, with genotyping of the protease/reverse transcriptase and integrase. We will perform matched integration site and proviral sequencing (MIP-Seq) on follow-up specimens with ongoing viremia, evidence of high-level ART adherence (by tenofovir diphosphate [TFV-DP] levels), and an active ART regimen (genotypic susceptibility score [GSS]?2). Results will identify individuals with resistance versus a hyperactive reservoir in the setting of pLLV. ,
|
Uganda |
2026-04-30 18:38:20 |
2029-04-30 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
WILLIAM MUSAMBA
ID:
|
Sub-ethnic Identities and Political Conflict in Uganda: The Case of Busoga (1900 to 1967)
REFNo: SS485ES
1)To analyze the influence of British colonial rule on the ethno-political conflicts in Busoga, 2)To assess the position of the Kyabazingaship (Paramount Chieftaincy) in the ethno-political conflicts in Busoga, 3)To examine the nature of political activism of the civic movements in Busoga namely, Young Busoga Association, the Abataka Association and the Abataka Mwoyo Gwa Busoga (Landlords are the Heart of Busoga), 4)To explore the attitude of post-colonial national leadership towards the ethno-political conflicts in Busoga.
|
Uganda |
2020-07-28 |
2023-07-28 |
Social Science and Humanities |
|
Degree Award |
|
Wilson Mugizi
ID: UNCST-2022-R009877
|
Resource Based View Approach in Implementation of E-Learning in Selected Ugandan Public Universities
REFNo: SS1454ES
i. To examine the relationship between universities tangible resources and e-learning implementation during and beyond Covid-19 pandemic era in Uganda
ii. To evaluate the relationship between the universities intangible resources and e-learning implementation during and beyond Covid-19 pandemic era in Uganda.
iii. To assess the relationship between universities capabilities and e-learning implementation during and beyond Covid-19 pandemic era in Uganda.
iv. To suggest the strategies for management of e-waste resulting from implementation e-learning implementation.
|
Uganda |
2022-11-08 14:03:00 |
2025-11-08 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
MICHAEL JACKSON WAKWABUBI
ID:
|
Financial distress in local governments in Uganda
REFNo: SS1429ES
To establish the relationship between local government delivery system and financial distress in local governments in Uganda
To assess the relationship between revenue concentration and financial distress in local governments in Uganda
To examine the relationship between revenue concentration, local governance, corruption and LG delivery system in local governments in Uganda
To assess the mediating effect of LG delivery system in the relationship between revenue concentration, local governance, corruption and financial distress in local governments in Uganda
To establish the relationship between local governance and financial distress in local governments in Uganda
To establish the relationship between corruption and financial distress in local governments in Uganda
|
Uganda |
2022-11-03 11:38:10 |
2025-11-03 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
MISAKI WAYENGERA
ID:
|
Prevalence of Polymorphic genes of Alzheimer disease in Nodding disease Tauopathy.
REFNo: HS726ES
To determine if polymorphisms in the eight common genes associated with Alzheimer Disease (APP, MAPT, PREN-1, PREN-2, BACE-1, BACE-2, IDE, and APOE-ε4) are present in DNA of Nodding Disease patients
|
Uganda |
2021-05-18 |
2024-05-18 |
Medical and Health Sciences |
|
Degree Award |
|
MISAKI WAYENGERA
ID:
|
DEVELOPMENT OF AFFORDABLE, EASY TO USE, AND RAPID POINT OF CARE DIAGNOSTIC TESTING PLATFORMS FOR COVID-19 SUITING REMOTE SETTINGS OF SUB-SAHARAN AFRICA.
REFNo: HS1648ES
1.To optimize and validate reagents (recombinant peptides, monoclonal and polyclonal antibodies)’s performance towards capture of SARS- CoV 2 virus antigen and host specific antibodies
2.To develop prototypes of lateral flow immunochromatography test (LFT) and tube-agglutination test platforms for COVID19 testing
3.To perform In-dependent validation of the developed test platforms.
|
Uganda |
2021-12-03 |
2024-12-03 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|